Literature DB >> 2972779

Direct evidence for the clustered nature of complement receptors type 1 on the erythrocyte membrane.

J P Paccaud1, J L Carpentier, J A Schifferli.   

Abstract

C receptors 1 (CR1) of human E are involved in the transport of C3b-coated immune complexes (IC) in the circulation. Many studies have suggested that the binding of IC to E is multivalent. This would require CR1 to be clustered on the cell membrane, but no direct evidence for such clustering is available. We studied the distribution of CR1 on human E by immunofluorescence and shadow-casting immuno-electron microscopy techniques with the use of a monoclonal anti-CR1 antibody followed by FITC- or gold-conjugated second antibodies, respectively. By immunofluorescence, CR1 appeared as small dots (clusters) on fixed and unfixed E prepared either at 4 degrees C or at 37 degrees C. In the same donor, the number of clusters varied extensively from cell to cell (e.g., 1 to 43 clusters/E for a donor with 520 CR1/cell), but the mean number of clusters per cell correlated significantly with the mean number of CR1/cell. These images contrasted with those obtained for Rhesus D (RhD) Ag used as controls (RhD Ag are known to be evenly distributed): only a faint uniform fluorescence was seen despite the presence of 10,000 antigenic sites. As determined by immunocytochemical method, more than 65% of the total gold particles were organized in clusters (2 to 15 gold particles/cluster) whether cells were prefixed or not. Quantitative determinations suggested that each gold particle corresponded to one CR1. The fraction of gold particles grouped into clusters of three or more receptors, the mean size of the clusters, and the maximal size of clusters correlated with the mean number of CR1 per cell. By contrast, RhD Ag were distributed homogeneously (less than 2% gold particles in clusters). These data are the first to demonstrate the preclustered nature of CR1 on E. Such distribution could explain the high binding efficiency of C3b-coated IC to E despite the low number of CR1 per cell.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2972779

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood.

Authors:  Ole-Lars Brekke; Bernt Christian Hellerud; Dorte Christiansen; Hilde Fure; Albert Castellheim; Erik Waage Nielsen; Anne Pharo; Julie Katrine Lindstad; Grethe Bergseth; Graham Leslie; John D Lambris; Petter Brandtzaeg; Tom Eirik Mollnes
Journal:  Mol Immunol       Date:  2011-08-11       Impact factor: 4.407

2.  Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment.

Authors:  R P Taylor; W M Sutherland; C J Reist; D J Webb; E L Wright; R H Labuguen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

3.  Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare.

Authors:  D J Birmingham; K F Gavit; S M McCarty; C Y Yu; B H Rovin; H N Nagaraja; L A Hebert
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

4.  Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: Polymorphisms, structure, and function of complement receptor 1.

Authors:  Jenny U Johansson; William D Brubaker; Harold Javitz; Andrew W Bergen; Denise Nishita; Abhishek Trigunaite; Andrés Crane; Justine Ceballos; Diego Mastroeni; Andrea J Tenner; Marwan Sabbagh; Joseph Rogers
Journal:  Alzheimers Dement       Date:  2018-05-21       Impact factor: 21.566

5.  The role of complement receptor type 1 (CR1, CD35) in determining the cellular distribution of opsonized immune complexes between whole blood cells: kinetic analysis of the buffering capacity of erythrocytes.

Authors:  C H Nielsen; S H Matthiesen; I Lyng; R G Leslie
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

6.  Near-field quantification of complement receptor 1 (CR1/CD35) protein clustering in human erythrocytes.

Authors:  Zachary J Lapin; Christiane Höppener; Harris A Gelbard; Lukas Novotny
Journal:  J Neuroimmune Pharmacol       Date:  2012-02-29       Impact factor: 4.147

Review 7.  Development of complement therapeutics for inhibition of immune-mediated red cell destruction.

Authors:  Karina Yazdanbakhsh
Journal:  Transfusion       Date:  2005-08       Impact factor: 3.157

8.  The anti-lipid A antibody HA-1A binds to rough gram-negative bacteria, fixes complement and facilitates binding to erythrocyte CR1 (CD35).

Authors:  M Tonoli; K A Davies; P J Norsworthy; J Cohen; M J Walport
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

9.  Quantitative analysis of C4Ab and C4Bb binding to the C3b/C4b receptor (CR1, CD35).

Authors:  B D Reilly; C Mold
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

10.  Peripheral catabolism of CR1 (the C3b receptor, CD35) on erythrocytes from healthy individuals and patients with systemic lupus erythematosus (SLE).

Authors:  J H Cohen; H U Lutz; J L Pennaforte; A Bouchard; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.